DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN

Abstract

The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA (SEQ ID NO:1)-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.

Claims

1. A T cell redirecting bispecific therapeutic which comprises (i) a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to (ii) a CD3 binding T cell redirection moiety, for use in a method of treating gp100 positive cancer in a patient comprising administering the bispecific therapeutic to said patient, wherein each dose is administered every 5-10 days, at least the first and second doses are below 40 g and the second dose is higher than the first dose.

2. The bispecific therapeutic for use of claim 1, wherein the method comprises administration of: (a) at least one first dose in the range of from 10-30 g; (b) at least one second dose in the range of from 20-40 g, wherein the or each second dose is higher than the first dose; and then (c) at least one dose of at least 50 g.

3. The bispecific therapeutic for use of claim 1 or claim 2, wherein each dose is administered is administered every 7 days.

4. The bispecific therapeutic for use of claim 1, 2 or 3, wherein the first dose is 20 g, the second dose is 30 g and/or the dose after the second dose is at least 50 g.

5. The bispecific therapeutic for use of any preceding claim, wherein two second doses are administered.

6. The bispecific therapeutic for use of any preceding claim, wherein the targeting moiety is a T cell receptor (TCR).

7. The bispecific therapeutic for use of claim 7, wherein the TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a TCR having the extracellular alpha chain sequence SEQ ID No: 2 and the extracellular beta chain sequence SEQ ID No: 3.

8. The bispecific therapeutic for use of any preceding claim, wherein the CD3 binding T cell redirection moiety is anti-CD3 antibody.

9. The bispecific therapeutic for use of claim 8 or claim 9, wherein the bispecific therapeutic includes a TCR alpha chain amino acid sequence selected from the group consisting of: (i) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is S; (ii) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is A; (iii) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is G; (iv) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is S, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 inclusive, based on the numbering of SEQ ID No: 2; (v) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is A, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 inclusive, based on the numbering of SEQ ID No: 2; (vi) the TCR alpha chain sequence of SEQ ID No: 2, wherein amino acids 1 to 109 are replaced by the sequence of SEQ ID No: 4, wherein amino acid at position 1 is G, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 inclusive, based on the numbering of SEQ ID No: 2; and a TCR beta chain-anti-CD3 amino acid sequence selected from the group consisting of: (vii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are D and I respectively; (viii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and I respectively; (ix) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and Q respectively; (x) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are D and I respectively amino acids at positions 108-131 are replaced by RTSGPGDGGKGGPGKGPGGEGTKGTGPGG (SEQ ID No: 6), and amino acids at positions 254-258 are replaced by GGEGGGSEGGGS (SEQ ID No: 7); (xi) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are D and I respectively and amino acid at position 257 is a S and amino acid at position 258 is a G; (xii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are D and I respectively and amino acid at position 256 is a S and amino acid at position 258 is a G; (xiii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are D and I respectively and amino acid at position 255 is a S and amino acid at position 258 is a G; (xiv) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and Q, and wherein amino acid at position 257 is a S and amino acid at position 258 is a G; (xv) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and Q, and wherein amino acid at position 256 is a S and amino acid at position 258 is a G; (xvi) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acids at positions 1 and 2 are A and Q, and wherein amino acid at position 255 is a S and amino acid at position 258 is a G; (xvii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acid at positions 1 and 2 are A and I respectively, and wherein amino acid at position 257 is a S and amino acid at position 258 is a G; (xviii) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acid at positions 1 and 2 are A and I respectively, and wherein amino acid at position 256 is a S and amino acid at position 258 is a G; (xix) the TCR beta chain-anti-CD3 sequence of SEQ ID No: 5, wherein amino acid at positions 1 and 2 are A and I respectively, and wherein amino acid at position 255 is a S and amino acid at position 258 is a G;

10. The bispecific therapeutic for use of claim 10, wherein: the alpha chain amino acid sequence is (i) and the beta chain-anti-CD3 amino acid sequence is (vii); the alpha chain amino acid sequence is (i) and the beta chain-anti-CD3 amino acid sequence is (x); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (ix); the alpha chain amino acid sequence is (v) and the beta chain-anti-CD3 amino acid sequence is (viii); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (vii); the alpha chain amino acid sequence is (i) and the beta chain-anti-CD3 amino acid sequence is (xi); the alpha chain amino acid sequence is (i) and the beta chain-anti-CD3 amino acid sequence is (xii); the alpha chain amino acid sequence is (i) and the beta chain-anti-CD3 amino acid sequence is (xiii); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xiv); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xv); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xvi); the alpha chain amino acid sequence is (v) and the beta chain-anti-CD3 amino acid sequence is (xvii); the alpha chain amino acid sequence is (v) and the beta chain-anti-CD3 amino acid sequence is (xviii); the alpha chain amino acid sequence is (v) and the beta chain-anti-CD3 amino acid sequence is (xix); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xi); the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xii); and the alpha chain amino acid sequence is (vi) and the beta chain-anti-CD3 amino acid sequence is (xiii).

11. The bispecific therapeutic for use of claim 11, wherein the alpha chain amino acid sequence is (v) and the beta chain-anti-CD3 amino acid sequence is (viii).

12. The bispecific therapeutic for use of any preceding claim, which is administered in combination with one or more anti-cancer therapies.

13. The bispecific therapeutic for use of claim 13, wherein the anti-cancer therapy is durvalumab, tremelimumab, galunisertib and merestinib.

14. The bispecific therapeutic for use of claim 14, wherein the anti-cancer therapy is merestinib and the dose of merestinib is in the range of from 40 to 120 mg once daily, preferably in the range of from 80 to 120 mg once daily.

15. The bispecific therapeutic for use of any preceding claim, wherein the gp100 positive cancer is melanoma.

16. A method of treating gp100 positive cancer in a patient comprising administering a T cell redirecting bispecific therapeutic to said patient, wherein each dose is administered every 5-10 days, at least the first and second doses are below 40 g and the second dose is higher than the first dose.

Description

REFERENCE IS MADE HEREIN TO THE ACCOMPANYING DRAWINGS IN WHICH

[0106] FIG. 1 shows the amino acid sequence of the alpha chain extracellular domain of the reference gp100 TCR (SEQ ID No; 2);

[0107] FIG. 2 shows the amino acid sequence of the beta chain extracellular domain of the reference gp100 TCR (SEQ ID No; 3);

[0108] FIG. 3 shows the amino acid sequence of a gp100-specific TCR a chain (SEQ ID No: 4);

[0109] FIG. 4 shows the amino acid sequence of an anti-CD3 scFv antibody fragment (bold type) fused via a linker, namely GGGGS (underlined), at the N-terminus of a gp100-specific TCR @chain (SEQ ID No 5);

[0110] FIG. 5 shows the occurrence of toxicities including severe and/or serious hypotension relative to the number of doses of IMCgp100;

[0111] FIG. 6 shows lymphocyte trafficking from the periphery following the first dose of IMCgp100;

[0112] FIG. 7 shows T cell proliferation with IMCgp100 in the presence or absence anti-CTLA-4;

[0113] FIG. 8 shows T cell proliferation with IMCgp100 in the presence or absence of anti- PD-L1;

[0114] FIG. 9 shows secretion of cytokines IFN, TNF and IL-2 with IMCgp100 in the presence or absence of anti-CTLA-4; and

[0115] FIG. 10 shows secretion of cytokine IFN with IMCgp100 in the presence or absence of anti-CTLA-4.

EXAMPLES

Example 1Identification of a Dosage Regimen for IMCgp100 which Ameliorates Drug-Related Severe Hypotension and Allows for an Increased Upper Dose

[0116] IMCgp100 is a T cell redirecting bispecific agent comprising a soluble affinity enhanced TCR that binds to the YLEPGPVTA (SEQ ID NO:1) peptide-HLA-A*02 complex, fused to an anti-CD3 scFv. [the alpha and beta chains of IMCgp100 are SEQ ID NOs 4 and 5 respectively] IMCgp100 was investigated in an first-in-human (FIH), open-label, dose finding study to assess the safety and tolerability of IMCgp100 in patients with advanced malignant melanoma (clinical trials identifier: NCT01211262). The study was designed to identify the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of IMCgp100 in 2 repeat dosing regimens: (Arm 1) weekly dosing (the RP2D-QW) and (Arm 2) daily dosing 4 days (the RP2D-QD).

[0117] Patients with stage IV or un-resectable stage Ill malignant melanoma were enrolled on the study. All patients were HLA-A*02 positive, were over 18 years of age, and were classified has having measurable disease according to RECIST 1.1 criteria, with a life expectancy in excess of three months and an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or below. There were no limits on the number of prior therapies. Patients were assessed for 33308/56652/FW/17875698.1 adequate haematologic, renal, hepatic, and cardiac function. Patients with symptomatic brain metastases were specifically excluded from the study. In total, 84 patients received treatment.

[0118] IMCgp100 was administered by intravenous infusion using a controlled infusion pump. Screening procedures and tests establishing eligibility were performed no more than 14 days before dosing with IMCgp100 commenced, except for HLA typing, MRI scan, ophthalmological, audiological and echocardiological assessments, which were performed within 28 days before dosing commenced. Informed consent was obtained from all patients. Blood samples for haematological, biochemical and pharmacokinetic (PK) analyses were obtained at screening, on day 1 prior to infusion, at 4, 10 and 24 hours following commencement of infusion and on days 2, 8 and 30.

[0119] Weekly Dosing: Dose Escalation Results

[0120] A standard 3+3 Phase I dose escalation protocol was followed to define the maximum tolerated dose (MTD). Briefly, the dose of IMCgp100 was escalated in cohorts of 3(+3) patients until criteria for MTD were met, or until the target limiting dose was reached. Dose escalation proceeded in three-fold increments, moving to a modified Fibonacci design according to safety and PK profile or if a dose limiting toxicity (DLT) was reported. MTD was defined as the highest dose level at which a DLT was experienced in greater than 33% of patients enrolled at that level. DLTs were observed within an 8-day window following treatment and were assessed following the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Transient Grade 3 or Grade 4 lymphopenia, and non-life threatening cutaneous skin rash were excluded as dose limiting criteria because of the anticipated pharmacological effects of the drug.

[0121] During dose escalation, 31 patients were treated across eight dose cohorts and received from 5 ng/kg to 900 ng/kg of drug. Dose limiting toxicity (DLT) of grade 3 or 4 hypotension was observed in four patients during dose escalation at 405 ng/kg (n=1 of 6), 600 ng/kg (n=1 of 6), and 900 ng/kg (n=2 of 6). In 3 of 4 DLT cases of grade 3 or 4 hypotension, the event occurred following the first dose of IMCgp100 at approximately 12-18 hours post-dose; 1 DLT hypotension event occurred with the second dose at 405 ng/kg, in a patient receiving concomitant antihypertensive therapy. Hypotension in these 4 cases was managed with IV fluids (normal saline and colloid infusions); none of the patients required pharmacologic (inotropic) support for blood pressure and all were treated with IV corticosteroid therapy. All cases of grade 3 or 4 hypotension resolved with fluid therapy and IV corticosteroid therapy within 2 days.

TABLE-US-00001 TABLE 1 Summary of dose limiting toxicities (DLTs) for weekly dose escalation Dose Level (ng/kg) N (patients) DLT Observed 5 3 15 3 45 3 135 3 270 3 405 6 One grade 3 hypotension.sup.a 600 6 One grade 4 hypotension.sup.a 900 4 Two grade 3 hypotension.sup.a DLT = dose limiting toxicity. .sup.aGrade 3 and 4 hypotension was associated with a significant and rapid decrease in peripheral lymphocyte count.

[0122] Based on this data, the MTD for weekly dosing was declared at 600 ng/kg.

[0123] Weekly Dosing: RP2D-QW Cohort Results

[0124] A review of the PK and safety data from the weekly dose escalation cohorts suggested that more severe toxicities and higher drug exposures of IMCgp100 were associated with higher absolute doses administered. Based on these data and the range of absolute doses administered at MTD of 600 ng/kg (n=5 pts, range 34-66 g QW, median dose of 54 g), the recommended phase 2 dose of the weekly dosing regimen (designated RP2D-QW) was initially determined to be a flat dose of 50 g administered on a weekly basis.

[0125] During this time, an additional three patients experienced adverse events involving grade 2 or greater hypotension. These events were observed to be confined to the first two doses (e.g. Cycle 1 Day 1 (C1D1) and Cycle 1 Day 8 (C1D8)) (FIG. 5). In an attempt to avoid severe hypotension events, the first dose of IMCgp100 was subsequently reduced to 40 g; however, hypotension (at grade ) was observed in a further two patients following dosing at C1 D1 and/or C1D8; in one patient, grade 2 hypotension was also experienced following the third dose.

[0126] No cases of severe hypotension were reported following subsequent doses. It should be noted that that the inventors observed a link between the frequency and severity of hypotension and the level of gp100 expression within the patient's tumours, patients with uveal melanoma having particularly high levels of gp100 expression and therefore at higher risk of toxicity.

[0127] A further 7 patients (6 uveal and 1 cutaneous melanoma) at high risk of toxicity due to the high levels of gp100 expression within tumours were enrolled on the weekly dose expansion phase received a first dose of 20 g (C1D1), followed by a second dose at 30 g (C1D8), finally moving to a flat dose of 50 g for the third dose and beyond. Surprisingly, no severe (grade ) hypotension was reported for these 7 patients despite their higher risk of experiencing gp100 expression mediated toxicities.

[0128] Table 2 below summarises the three dosage regimens used in the study, the number of patients treated on each regimen and the number of hypotension adverse events that were reported.

TABLE-US-00002 TABLE 2 Summary of weekly dosage regimens and hypotension events No. hypotension events Weekly Regimen No. patients Grade 2 Grade 3 Grade 4 Flat dose 35 4 4 1 (600/900 ng/kg/50 g) 40 g (C1D1) - 50 g 3 2 2 0 20 g (C1D1) - 30 g 7 1 0 0 (C1D8) - 50 g

[0129] These data demonstrate the surprising benefit of a two-step intra-patient dose escalation regimen, in ameliorating drug-related severe hypotension when treating patients with gp100 positive cancers.

[0130] Hypotension results from lymphocyte trafficking and cytokine release Analysis of blood from a subset of patients dosed at weekly RP2D showed marked lymphocyte trafficking after IMCgp100 had been administered. Lymphocyte levels dropped substantially at about 12-24h post-infusion, returning to baseline levels by Day 8. This effect was more profound in cases with severe and/or serious hypotension (FIG. 6). Cytokine analyses revealed modest levels of one or more inflammatory cytokines. The greatest increases observed in the periphery were in the levels of tissue chemoattractant chemokines that parallel the transient drop in peripheral circulating lymphocytes generally resolving by 48 hours after dosing and reaching pre-dose levels by Day 8.

[0131] Further Testing of Intra-Patient Dosage Regimen

[0132] A retrospective review of the tumour response data from the patients treated in the above Phase 1 study generally noted objective responses were obtained in patients who received higher absolute doses (approximately 65-85 g). It was therefore hypothesised that using 20 g at C1D1 and 30 g at C1D8 may allow for higher absolute doses, i.e. above 50 g, at Cycle 1 Day 15 (C1D15) and beyond, and potentially improve efficacy.

[0133] To test this, IMCgp100 is being further investigated in an ongoing phase I open-label, multi-centre study in patients with advanced uveal melanoma (clinical trial identifier: NCT02570308). The first part of the study follows a standard 3+3 dose escalation design. The first cohort of patients have received IMCgp100 administered by intravenous infusion at a fixed dose of 20 g at C1D1 and 30 g at C1D8, followed by dosing at 60 g from C1D15. Initial data indicate no severe hypotension-related events were reported for patients in this cohort (n=3). Further cohorts of patients will receive higher doses at C1D15 (e.g. 70 g, 80 g or higher).

Example 2Evidence for Increased Risk of Severe Hypotension for IMCgp100 Administered in Combination with Other Immune-Modulating Drugs

[0134] IMCgp100-mediated immune activation was investigated in vitro in the presence or absence of checkpoint inhibitor antibodies against PD-L1/PD-1 and CTLA-4.

[0135] Increased potency of T cell response with IMCgp100 in combination with anti-CTLA-4 In this experiment T cell proliferation was used as read-out for potency. IMCgp100 was used at a concentration of 80 M in the presence or absence of 40 ug/ml anti-CTLA-4 (clone L3D10; Biolegend). HLA-A*02 positive monocytes pulsed with 10 nM or 100 nM gp100 peptide were used as target antigen presenting cells and plated at 10,000 cells/well. Effector CD3+ T cells were labelled with Cell Tracker Violet. T cell proliferation was measured after 5 days using the FACS based Intellicyt assay.

[0136] The results presented in FIG. 7 show that IMCgp100 in combination with anti CTLA-4 results in an improved T cell response (at lower peptide concentrations) relative to IMCgp100 alone, indicating a potential for higher levels of both efficacy and gp100 specific on-target, off-tumour toxicity in patients treated with this combination relative to IMCgp100 monotherapy.

[0137] Increased potency of T cell killing with IMCgp100 in combination with anti-PD-L1 In this experiment, T cell killing was used as read-out for potency. IMCgp100 was used at a concentration of 80 M and 100 M in the presence or absence of 10 ug/ml anti-PD-L1 (clone 29E.2A3; BioLegend). HLA-A*02 positive Me1624 cells were used as target antigen presenting cells. CD8+ T cells were used as effector cells at an effector target ratio of 5:1. T cell killing was measured using the Incucyte ZOOM assay over 3 days. Caspase- 3/7 activation in target cells was monitored as a measure of apoptosis (imaged every 2 hours).

[0138] The results presented in FIG. 8 show that IMCgp100 in combination with anti PD-L1 results in augmented T cell killing relative to IMCgp100 alone, indicating a potential for higher levels of both efficacy and gp100 specific on-target, off-tumour toxicity in patients treated with this combination relative to IMCgp100 monotherapy.

[0139] Increased Production of Pro-Inflammatory Cytokines with IMCgp100 in Combination with Anti-CTLA-4 or anti-PD-L1

[0140] In this experiment, cytokine secretion was assessed using the V-PLEX human pro-inflammatory panel 1 assay kit from Meso Scale Discovery.

[0141] For IMCgp100 in combination with anti-CTLA-4 and anti-PD-L1, supernatant samples were taken at 24h from the proliferation assay and the killing assay respectively.

[0142] The data shown in FIG. 9 demonstrate augmented secretion of IFN, TNF and IL-2 (at low peptide concentrations) in the presence of IMCgp100 and anti-CTLA-4, relative to IMCgp100 alone.

[0143] The data shown in FIG. 10 demonstrate augmented secretion of IFN in the presence of IMCgp100 and anti-PD-L1, relative to IMCgp100 alone.

[0144] These data demonstrate increased immune activation with IMCgp100 combination therapy relative to IMCgp100 monotherapy, and therefore a potential increased risk of severe hypotension for patients receiving the combination therapy, due to on-target off-tumour targeting of gp100 positive melanocytes.